The old adage that drinking beer before wine prevents hangovers turns out to be a myth, German researchers say.

Bankers are diagnosing another robust year for U.S. healthcare lending as the first two big loans of 2019 include the largest-ever tie-up in the pharmaceutical sector, and more are expected.

Unilever is to buy GlaxoSmithKline’s Horlicks nutrition business for $3.8 billion, boosting the Anglo-Dutch group’s position in India by adding the popular malted drink.

Coca-Cola Co. is closely watching the growing marijuana-infused drinks market, responding to a media report that the world’s largest beverage maker was in talks with Canada’s Aurora Cannabis Inc.

Low-calorie sweetened beverages such as diet sodas that use aspartame or stevia may be a good replacement for full-sugar sodas and fruit juices, but researchers are still unsure about their long-term health effects, according to a new American Heart Association Science Advisory.

Colon cancer patients who drink one or more servings of artificially sweetened beverages a day have roughly half the risk of their cancer recurring compared to those who drink few or none of these beverages, a U.S. study suggests.

Beer cannot be marketed as beneficial, a German top court ruled after a consumer rights group sued a brewery on the basis that its advertisement falsely suggested the beer had health benefits.

 
 

At-home consumption and gourmet beverages have Americans drinking a daily cup of coffee at the highest level since 2012.

People who drink hot tea daily may be less likely than others to develop glaucoma symptoms, U.S. researchers say.

GlaxoSmithKline provided information about its second-quarter financials this week. The attention focused on plans to kill more than 30 preclinical and clinical programs and allocate 80 percent of its research-and-development budget to respiratory and HIV/infectious diseases. But a closer look at new CEO Emma Walmsley’s plans point to big changes in the company’s manufacturing network as well.